Automate Your Wheel Strategy on NAMSW
With Tiblio's Option Bot, you can configure your own wheel strategy including NAMSW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NAMSW
- Rev/Share 0.4059
- Book/Share 6.6942
- PB 2.8278
- Debt/Equity 0.0005
- CurrentRatio 19.9766
- ROIC -0.2439
- MktCap 2125290030.0
- FreeCF/Share -1.1801
- PFCF -15.5088
- PE -11.7329
- Debt/Assets 0.0005
- DivYield 0
- ROE -0.3295
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About NewAmsterdam Pharma Company N.V. (NAMSW)
- IPO Date 2021-02-10
- Website https://www.newamsterdampharma.com
- Industry Biotechnology
- CEO Dr. Michael Harvey Davidson FACC, Facp., M.D.
- Employees 68
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.